HIGHLIGHTS
- who: Sahar H. Elhini and collaborators from the Diabetes and Endocrinology Unit, Internal Medicine Department, Faculty of Medicine, University, Department of Pharmacy Practice, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia have published the research: The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients, in the Journal: Pharmaceuticals 2022, 1516 of /2022/
- what: The authors aimed to assess the differences between empagliflozin and ursodeoxycholic acid in terms of safety and efficacy as add-on therapy in regressing LFC and fibrosis in type 2 diabetic patients with NAFLD. This study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.